Madrigal Pharmaceuticals(MDGL)
WEST CONSHOHOCKEN, PAPharmaceutical
Focus: Madrigal Pharmaceuticals is a public specialty pharma company focused on small-molecule therapeutics for metabolic liver disease and neurology. The company has one marketed product (Rezdiffra/resmetirom) and is actively building a pipeline around thyroid hormone receptor beta agonists.
Profile data last refreshed 11h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
64+29 this month
Hot — 53 jobs added in 30d
Net +29 (53 new, 24 removed). Aggressive expansion phase.
Should You Work at Madrigal Pharmaceuticals?
AI assessmentEarly-stage specialty pharma with one approved asset and significant runway to prove pipeline; best for growth-stage professionals comfortable with execution risk and metabolic disease focus.
Why Work Here
- One FDA-approved product (Rezdiffra) in growth phase with long patent protection until 2045, providing commercial stability
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Key Products
Help build intelligence for Madrigal Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.